Locations
Shanghai, China · Shanghai, China
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Series C+
founded in
2010
Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China, focusing on unmet medical needs by developing novel therapies for global patients. The company has a strong emphasis on diabetes treatment, with its core product, Huadongning® (Dorzagliatin), which enhances glucose sensitivity in Type 2 diabetes patients. Approved by the NMPA in September 2022, it can be used alone or in combination with Metformin, and is suitable for patients with varying degrees of renal impairment. Hua Medicine collaborates with Bayer for the commercialization of Huadongning® in China, aiming to benefit diabetes patients and their families. The company is committed to continuous innovation and aims to lead global diabetes medical innovation.
Something looks off?